157 related articles for article (PubMed ID: 31732254)
1. Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
Ni S; Chen X; Yu Q; Xu Y; Hu Z; Zhang J; Zhang W; Li B; Yang X; Mao F; Huang J; Sun Y; Li J; Jia L
Eur J Med Chem; 2020 Jan; 185():111848. PubMed ID: 31732254
[TBL] [Abstract][Full Text] [Related]
2. Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
Chen X; Yang X; Mao F; Wei J; Xu Y; Li B; Zhu J; Ni S; Jia L; Li J
Eur J Med Chem; 2021 Jan; 210():112964. PubMed ID: 33129593
[TBL] [Abstract][Full Text] [Related]
3. Overactivated neddylation pathway as a therapeutic target in lung cancer.
Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
[TBL] [Abstract][Full Text] [Related]
4. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression in vitro and in vivo.
Fu DJ; Song J; Zhu T; Pang XJ; Wang SH; Zhang YB; Wu BW; Wang JW; Zi X; Zhang SY; Liu HM
Eur J Med Chem; 2020 Apr; 192():112153. PubMed ID: 32135407
[TBL] [Abstract][Full Text] [Related]
6. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 1,2,4-triazine-based derivatives as novel neddylation inhibitors and anticancer activity studies against gastric cancer MGC-803 cells.
Song J; Cui XX; Wu BW; Li D; Wang SH; Shi L; Zhu T; Zhang YB; Zhang SY
Bioorg Med Chem Lett; 2020 Jan; 30(2):126791. PubMed ID: 31740251
[TBL] [Abstract][Full Text] [Related]
8. Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Ebiike H; Taka N; Matsushita M; Ohmori M; Takami K; Hyohdoh I; Kohchi M; Hayase T; Nishii H; Morikami K; Nakanishi Y; Akiyama N; Shindoh H; Ishii N; Isobe T; Matsuoka H
J Med Chem; 2016 Dec; 59(23):10586-10600. PubMed ID: 27933954
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a cinnamyl piperidine derivative as new neddylation inhibitor for gastric cancer treatment.
Wang B; Zhang QH; Li XJ; Wang SQ; Chen XB; Yu B; Liu HM
Eur J Med Chem; 2021 Dec; 226():113896. PubMed ID: 34624825
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
Lelais G; Epple R; Marsilje TH; Long YO; McNeill M; Chen B; Lu W; Anumolu J; Badiger S; Bursulaya B; DiDonato M; Fong R; Juarez J; Li J; Manuia M; Mason DE; Gordon P; Groessl T; Johnson K; Jia Y; Kasibhatla S; Li C; Isbell J; Spraggon G; Bender S; Michellys PY
J Med Chem; 2016 Jul; 59(14):6671-89. PubMed ID: 27433829
[TBL] [Abstract][Full Text] [Related]
11. NAE modulators: A potential therapy for gastric carcinoma.
Liang Q; Liu M; Li J; Tong R; Hu Y; Bai L; Shi J
Eur J Med Chem; 2022 Mar; 231():114156. PubMed ID: 35131538
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the 2,4-disubstituted quinazoline derivative as a novel neddylation inhibitor for tumor therapy.
Su J; Li M; Chang Y; Jia M; Zhao M; Guan S; Niu J; Zhang S; Yang H; Sun M
Bioorg Chem; 2024 Apr; 145():107237. PubMed ID: 38442613
[TBL] [Abstract][Full Text] [Related]
13. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.
Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y
Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical Inhibition of Neddylation as Promising Treatments for Various Cancers.
Yin L; Xue Y; Shang Q; Zhu H; Liu M; Liu Y; Hu Q
Curr Top Med Chem; 2019; 19(12):1059-1069. PubMed ID: 30854973
[TBL] [Abstract][Full Text] [Related]
15. Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
Wu KJ; Zhong HJ; Li G; Liu C; Wang HD; Ma DL; Leung CH
Eur J Med Chem; 2018 Jan; 143():1021-1027. PubMed ID: 29232579
[TBL] [Abstract][Full Text] [Related]
16. A novel NAE/UAE dual inhibitor LP0040 blocks neddylation and ubiquitination leading to growth inhibition and apoptosis of cancer cells.
Lu P; Guo Y; Zhu L; Xia Y; Zhong Y; Wang Y
Eur J Med Chem; 2018 Jun; 154():294-304. PubMed ID: 29843100
[TBL] [Abstract][Full Text] [Related]
17. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
Naka T; Kubo K; Inada Y; Nishikawa K
Drug Des Discov; 1999 Aug; 16(2):95-108. PubMed ID: 10533806
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate.
Song Y; Lin X; Kang D; Li X; Zhan P; Liu X; Zhang Q
Eur J Med Chem; 2014 Jul; 82():293-307. PubMed ID: 24922544
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation.
Yan W; Wang X; Dai Y; Zhao B; Yang X; Fan J; Gao Y; Meng F; Wang Y; Luo C; Ai J; Geng M; Duan W
J Med Chem; 2016 Jul; 59(14):6690-708. PubMed ID: 27348537
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer.
Lin Y; Liu R; Zhao P; Ye J; Zheng Z; Huang J; Zhang Y; Gao Y; Chen H; Liu S; Zhou J; Chen C; Chen H
Eur J Med Chem; 2018 Feb; 146():354-367. PubMed ID: 29407962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
